Request Demo
Barinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024
Clinical ResultImmunotherapyClinical Study
Two abstracts highlighting the Company's lead hepatitis B-focused asset will be presented as poster and oral presentations.
More mature interim data to be presented at EASL following abstract data cuts earlier in the year may indicate potential rates of functional cure.
May 22, 2024 -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (the Company), a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer, today announced clinical data from the Company's hepatitis B-focused immunotherapeutic candidate, VTP-300, will be highlighted in poster and oral presentations at the European Association for the Study of the Liver (EASL) Congress, taking place June 5-8, 2024, in Milan, Italy.
“We are pleased to present the latest data on our immunotherapeutic candidate, VTP-300, at EASL 2024 updated from the data cut we made in January for the abstracts,” said Bill Enright, CEO of Barinthus Bio. “Hepatitis B is considered to be a 'silent epidemic' because most people are asymptomatic while infected, allowing the disease to slowly damage the liver. We understand chronic HBV profoundly impacts the quality of life for people living with the disease, and we are excited to share our ongoing research efforts with the overall goal of a working towards a functional cure.”
Abstract Acceptances:
Abstract number: 2823
Presentation type: Poster presentation
Presentation time: Wednesday, 05 June, 08:30-18:00 CET.
Authors: MF. Yuen, WL. Chuang, CJ. Liu, A. Leerapun, P. Tangkijvanich, L. Bussey, R. Kolenovska, M. Downs, K. Anderson, A. Vardeu, D. Tait.
Key Findings: Preliminary data suggest VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hepatitis B surface antigen (HBsAg) across all groups. Additional interim data, including NUC discontinuation, Hepatitis B Virus (HBV) markers, immunology and safety data will be presented in the poster.
Abstract number: 505
Presentation type: Oral presentation
Title: Imdusiran (AB-729) administered every 8 weeks for 24 weeks followed by the immunotherapeutic VTP-300 maintains lower HBV surface antigen levels in NUC-suppressed CHB subjects than 24 weeks of imdusiran alone.
Presentation time: Thursday, 06 June, 17:00-18:15 CET
Authors: K. Agarwal, MF. Yuen, S. Roberts, GH. Lo, CW. Hsu, WL. Chuang, CY. Chen, PY. Su, S. Galhenage, SS. Yang, EP. Thi, K. Anderson, D. Antoniello, E. Medvedeva, T. Eley, T. Varughese, L. Bussey, C. Davis, A. Vardeu, CL. Espiritu, SC. Ganchua, C. Iott, E. Eill, T. Evans, KD. Sims.
Key Findings: Imdusiran administered for 24 weeks followed by VTP-300 was generally well-tolerated and resulted in lower HBsAG levels than placebo at week 60. Additionally, more subjects that received VTP-300 qualified to stop NUC therapy than placebo. On-treatment, follow-up and NUC discontinuation data including HBV parameters and immunology data will be included in the oral presentation.
About VTP-300
VTP-300 is an immunotherapeutic candidate consisting of an initial dose using the ChAdOx vector and a secondary dose(s) using the MVA vector, both encoding multiple hepatitis B antigens, including full-length surface, modified polymerase, and core antigens. VTP-300 is the first antigen-specific immunotherapy that has been shown to induce sustained reductions in HBsAg. Barinthus Bio is studying VTP-300 in combination with other agents, including siRNA and low-dose anti-PD-1 antibodies, to control the infection and counterbalance the immune suppression and T cell exhaustion in the liver caused by chronic HBV infection.
About HBV
Globally it is estimated that there are approximately 254 million people, including up to 2.4 million in the U.S. and 10.6 million in Europe, living with chronic HBV infection, with the highest prevalence in East Asia and Africa.1,2 Approximately 1.1 million people died from HBV and related complications in 2022, such as liver cirrhosis and hepatocellular carcinoma.1 Due to low HBV diagnosis rates, only 13% of people living with chronic hepatitis B are aware of their infection and less than 3% had received antiviral treatment at the end of 2022.1
About Barinthus Biotherapeutics
Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Bio. With a broad pipeline, built around three proprietary platform technologies: ChAdOx, MVA and SNAP, Barinthus Bio is advancing a pipeline of four product candidates across a diverse range of therapeutic areas, including: VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-Tolerance Immunotherapy (TI) platform to treat patients with celiac disease; and VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer. Barinthus Bio’s proven scientific expertise, diverse portfolio and focus on pipeline development uniquely positions the company to navigate towards delivering treatments for people with infectious diseases, autoimmunity and cancers that have a significant impact on their everyday lives. For more information, visit www.barinthusbio.com.
References
WHO, Global hepatitis report 2024.
Hepatitis B Foundation, What is Hepatitis B?, 2023.
The content above comes from the network. if any infringement, please contact us to modify.
Organizations
Indications
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.